{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:52:05Z","timestamp":1779911525622,"version":"3.53.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Mesenchymal stromal cells (MSCs) were identified more than 50 years ago, and research advances have promoted the translation of pre-clinical studies into clinical settings in several diseases. However, we are only starting to uncover the local factors that regulate cell phenotype, cell function, and cell viability across tissues following administration in different diseases. Advances in pre-clinical and translational studies suggest that the host environment, especially inflammatory active environments, plays a significant role in directing the infused MSCs towards different phenotypes with different functions. This can significantly effect their therapeutic efficacy. One way to study this interaction between the host environment and the infused cells is to expose MSCs <jats:italic>ex vivo<\/jats:italic> to patient samples such as serum or bronchoalveolar lavage fluid. Using this approach, it has been demonstrated that MSCs are very sensitive to different host factors such as pathogens, inflammatory cytokines, and extra cellular matrix properties. By understanding how different local host factors effect MSC function it will open possibilities to select specific patient sub-groups that are more likely to respond to this type of treatment and will also open possibilities to prime the local host environment to increase viability and to enrich for a specific MSC phenotype. Here, we aim to review the current understanding of the interaction of MSCs with the host microenvironment. To narrow the scope of this mini review, the focus will be on the pulmonary microenvironment, with a specific focus on the diseases acute respiratory distress syndrome (ARDS) and cystic fibrosis (CF).<\/jats:p>","DOI":"10.3389\/fimmu.2022.1072257","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T06:08:20Z","timestamp":1668492500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["MSCs interaction with the host lung microenvironment: An overlooked aspect?"],"prefix":"10.3389","volume":"13","author":[{"given":"Daniel J.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rolandsson Enes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","article-title":"Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial","volume":"3","author":"Wilson","year":"2015","journal-title":"Lancet Respir Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2094","article-title":"A placebo-controlled, randomized trial of mesenchymal stem cells in COPD","volume":"143","author":"Weiss","year":"2013","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.jpeds.2013.12.011","article-title":"Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial","volume":"164","author":"Chang","year":"2014","journal-title":"J Pediatr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jpeds.2019.02.029","article-title":"Safety of intratracheal administration of human umbilical cord blood derived mesenchymal stromal cells in extremely low birth weight preterm infants","volume":"210","author":"Powell","year":"2019","journal-title":"J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30418-1","article-title":"Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial","volume":"7","author":"Matthay","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.04.003","article-title":"Manufacturing mesenchymal stromal cells for clinical applications: A survey of good manufacturing practices at U.S. academic centers","volume":"21","author":"Phinney","year":"2019","journal-title":"Cytotherapy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.015","article-title":"Manufacturing mesenchymal stromal cells for the treatment of graft-versus-Host disease: A survey among centers affiliated with the European society for blood and marrow transplantation","volume":"24","author":"Trento","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/stcltm\/szab009","article-title":"Definition and characteristics of mesenchymal stromal cells in preclinical and clinical studies: A scoping review","volume":"11","author":"Renesme","year":"2022","journal-title":"Stem Cells Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R114.619304","article-title":"Complexity of danger: the diverse nature of damage-associated molecular patterns","volume":"289","author":"Schaefer","year":"2014","journal-title":"J Biol Chem"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-010-1048-7","article-title":"Innate immunity in the human lung: pathogen recognition and lung disease","volume":"343","author":"Rohmann","year":"2011","journal-title":"Cell Tissue Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/path.4124","article-title":"Danger-associated molecular patterns (DAMPs) in acute lung injury","volume":"229","author":"Tolle","year":"2013","journal-title":"J Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0055-2021","article-title":"The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects","volume":"30","author":"Van den Bossche","year":"2021","journal-title":"Eur Respir Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3620","article-title":"Role of the extracellular matrix in regulating stem cell fate","volume":"14","author":"Watt","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.06.044","article-title":"Matrix elasticity directs stem cell lineage specification","volume":"126","author":"Engler","year":"2006","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24530","article-title":"Mucus, mucins, and cystic fibrosis","author":"Morrison","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"a009589","DOI":"10.1101\/cshperspect.a009589","article-title":"CFTR, mucins, and mucus obstruction in cystic fibrosis","volume":"2","author":"Kreda","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.celrep.2019.03.086","article-title":"Direct lung sampling indicates that established pathogens dominate early infections in children with cystic fibrosis","volume":"27","author":"Jorth","year":"2019","journal-title":"Cell Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1465-9921-4-8","article-title":"State of the art: why do the lungs of patients with cystic fibrosis become infected and why can\u2019t they clear the infection","volume":"4","author":"Chmiel","year":"2003","journal-title":"Respir Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2174\/1389450117666151209120516","article-title":"Dysregulated chemokine signaling in cystic fibrosis lung disease: A potential therapeutic target","volume":"17","author":"Guan","year":"2016","journal-title":"Curr Drug Targets"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.04.010","article-title":"Increase in interleukin-8 production from circulating neutrophils upon antibiotic therapy in cystic fibrosis patients","volume":"11","author":"Montemurro","year":"2012","journal-title":"J Cyst Fibros"},{"key":"B22","doi-asserted-by":"publisher","first-page":"L997","DOI":"10.1152\/ajplung.00156.2002","article-title":"Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis","volume":"284","author":"Corvol","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00218.2020","article-title":"Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells","volume":"319","author":"Abreu","year":"2020","journal-title":"Am J Physiology-Lung Cell Mol Physiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01485-4","article-title":"Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes","volume":"400","author":"Bos","year":"2022","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201211-1981OC","article-title":"Comparison of the Berlin definition for acute respiratory distress syndrome with autopsy","volume":"187","author":"Thille","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1152\/physrev.00003.2002","article-title":"Lung epithelial fluid transport and the resolution of pulmonary edema","volume":"82","author":"Matthay","year":"2002","journal-title":"Physiol Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00875.2007","article-title":"STAT-3 regulates surfactant phospholipid homeostasis in normal lung and during endotoxin-mediated lung injury","volume":"104","author":"Ikegami","year":"2008","journal-title":"J Appl Physiol (1985)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00372.2007","article-title":"Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity","volume":"294","author":"Bastarache","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1165\/rcmb.2005-0425OC","article-title":"Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation","volume":"36","author":"Wang","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00263.2019","article-title":"Lung inflammatory environments differentially alter mesenchymal stromal cell behavior","volume":"317","author":"Abreu","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201701-0170OC","article-title":"Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer","volume":"196","author":"Morrison","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04149-2020","article-title":"Healthy versus inflamed lung environments differentially affect mesenchymal stromal cells","volume":"58","author":"Rolandsson Enes","year":"2021","journal-title":"Eur Respir J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.18-0236","article-title":"Mesenchymal stem cells reconditioned in their own serum exhibit augmented therapeutic properties in the setting of acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2019","journal-title":"Stem Cells Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00977","article-title":"Metabolism in human mesenchymal stromal cells: A missing link between hMSC biomanufacturing and therapy","volume":"10","author":"Yuan","year":"2019","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-016-9690-4","article-title":"The role of autophagy in the maintenance of stemness and differentiation of mesenchymal stem cells","volume":"12","author":"Sbrana","year":"2016","journal-title":"Stem Cell Rev Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e85040","DOI":"10.1371\/journal.pone.0085040","article-title":"Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells","volume":"9","author":"Moll","year":"2014","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2013.0193","article-title":"Mesenchymal stem cells induce an inflammatory response after intravenous infusion","volume":"22","author":"Hoogduijn","year":"2013","journal-title":"Stem Cells Dev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e21703","DOI":"10.1371\/journal.pone.0021703","article-title":"Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses","volume":"6","author":"Moll","year":"2011","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.isci.2019.04.011","article-title":"The plasticity of mesenchymal stem cells in regulating surface HLA-I","volume":"15","author":"Wang","year":"2019","journal-title":"iScience"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225680","article-title":"The importance of HLA assessment in \u201cOff-the-Shelf\u201d allogeneic mesenchymal stem cells based-therapies","volume":"20","author":"Kot","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1038\/s41598-021-83894-7","article-title":"Intra-vital imaging of mesenchymal stromal cell kinetics in the pulmonary vasculature during infection","volume":"11","author":"Masterson","year":"2021","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e10088","DOI":"10.1371\/journal.pone.0010088","article-title":"A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype","volume":"5","author":"Waterman","year":"2010","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S296161","article-title":"Priming leukemia with 5-azacytidine enhances CAR T cell therapy","volume":"10","author":"Xu","year":"2021","journal-title":"Immunotargets Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.11.003","article-title":"Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease","volume":"10","author":"Posthuma","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000166","article-title":"Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I\/II study","volume":"8","author":"Verdegaal","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.2012.1841","article-title":"The epidemiological consequences of immune priming","volume":"279","author":"Tidbury","year":"2012","journal-title":"Proc Biol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1072257\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T06:08:23Z","timestamp":1668492503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1072257\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2022.1072257"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1072257","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"article-number":"1072257"}}